Stathmin is the founding member of a family of microtubule-destabilizing proteins that have a critical role in the regulation of mitosis. Stathmin is expressed at high levels in breast cancer and its overexpression is linked to disease progression. Although there is a large body of evidence to support a role for stathmin in breast cancer progression, the validity of stathmin as a viable therapeutic target for breast cancer has not been investigated. Here, we used a bicistronic adenoviral vector that co-expresses green fluorescent protein and a ribozyme that targets stathmin messenger RNA in preclinical breast cancer models with different estrogen receptor (ER) status. We examined the effects of anti-stathmin ribozyme on the malignant phenotype of breast cancer cells in vitro and in xenograft models in vivo both as a single agent and in combination with chemotherapeutic agents. Adenovirus-mediated gene transfer of anti-stathmin ribozyme resulted in a dose-dependent inhibition of proliferation and clonogenicity associated with a G2/M arrest and increase in apoptosis in both ER-positive and ER-negative breast cancer cell lines. This inhibition was markedly enhanced when stathmin-inhibited breast cancer cells were exposed to low concentrations of taxol, which resulted in virtually complete loss of the malignant phenotype. Interestingly, breast cancer xenografts treated with low doses of anti-stathmin therapy and taxol showed regression in a majority of tumors, while some tumors stopped growing completely. In contrast, combination of anti-stathmin ribozyme and adriamycin resulted in only a modest inhibition of growth in vitro and in breast cancer xenografts in vivo. Although inhibition of tumor growth was observed in both the combination treatment groups compared with groups treated with single agent alone, combination of anti-stathmin therapy and taxol had a more profound inhibition of tumorigenicity, as both agents target the microtubule pathway. Clinically, these findings are highly relevant because taxol is one of the most active chemotherapeutic agents in breast cancer. These studies provide the proofof-principle that stathmin provides an attractive molecular target, which could serve as a primary focus of novel approaches to breast cancer.
INTRODUCTION
Stathmin (also known as oncoprotein 18, p18, Lap 18, metablastin) is one of the key regulators of the mitotic spindle and the microtubule cytoskeleton during cell cycle progression. 1, 2 The level of expression and the state of phosphorylation of stathmin are modulated in response to a variety of signals that affect the proliferation and/or differentiation of eukaryotic cells. [3] [4] [5] Stathmin undergoes a significant increase in its phosphorylation as cells proceed from the S phase to the G2-M phases of the cell cycle. 6 This increase in the phosphorylation of stathmin is mediated by p34 cdc2 kinase, mitogen-activated protein kinase and other kinases. 6, 7 A direct role of stathmin in mitosis came from genetic studies that showed that manipulation of stathmin expression results in mitotic arrest associated with severe spindle abnormalities and growth inhibition. 2, 6, 7 Subsequent studies led to the identification of stathmin as a cellular factor, which promotes microtubule depolymerization by increasing the rate of catastrophe. 8 The microtubule-depolymerizing activity of stathmin is regulated by changes in its state of phosphorylation. 2, 9, 10 Changes in the phosphorylation of stathmin has a critically important role in the remodeling of the microtubule network during mitotic progression. For instance, the phosphorylation of stathmin at entry into mitosis switches off its microtubule-depolymerizing activity, allowing the spindle to be formed. 2 At late mitosis, dephosphorylation of stathmin is necessary for the disassembly of the mitotic spindle, exit from mitosis and entry into a new cell cycle. 10, 11 With these important discoveries, stathmin became the founding member of a novel family of microtubule-destabilizing proteins whose function is regulated by cell-cycle-specific phosphorylation.
Stathmin is expressed at high levels in breast carcinoma and other human malignancies. [12] [13] [14] Interestingly, high levels of stathmin expression in breast carcinoma correlates with the more aggressive disease with bad prognostic features. 12, 15 More importantly, the level of stathmin expression in breast cancer patients correlates negatively with estrogen receptor (ER) expression and positively with proliferating cell nuclear antigen expression, tumor size and histopathological grade. 12, 15, 16 In addition, the overexpression of stathmin was found to correlate with larger tumor size, high tumor grade and high tumor stage. 12, 16 Thus, the high level of stathmin expression in breast cancer may be a critical component of the high proliferative rates of breast cancer cells. Interestingly, when biopsy specimens from breast cancer were immunostained with an anti-stathmin antibody, strong immunoreactivity was observed in poorly differentiated tumors than in well-differentiated tumors.
Furthermore, Oishi et al. 17 demonstrated very strong stathmin immunoreactivity in breast cancer patients with supraclavicular lymph node metastasis, thus providing a powerful tool for predicting the outcome of breast cancer patients. This suggests that overexpression of stathmin in breast cancer is directly linked to breast tumor progression. In another study, stathmin was identified as a gene that promotes invasion of breast cancer cells and may serve as a useful diagnostic marker for invasive breast cancer. 18 Studies of Saal et al., 19 on the other hand, demonstrated that the phosphotidylinositol 3-kinase pathway is frequently activated in breast cancer and the loss of phosphatase and tensin homolog, the negative regulator of phosphotidylinositol 3-kinase, results in robust activation of this pathway. High levels of stathmin were found to be associated with phosphatase and tensin homolog-negative tumors that predicted distant metastasis. 19 This group proposed that stathmin can serve as a surrogate marker of phosphatase and tensin homolog/phosphotidylinositol 3-kinase signature and had prognostic significance associated with breast cancer metastasis and poor survival. 19 Overall, the level of stathmin expression directly correlates with the malignant behavior of breast cancer cells and serves as an important prognostic marker that predicts survival in breast cancer.
Although there is a large body of evidence to support the role of stathmin in breast cancer progression, the validity of stathmin as a therapeutic target for breast cancer has not been fully investigated. Stathmin provides an attractive molecule to target in breast cancer therapy, which aims to disrupt the mitotic apparatus of dividing cells. Moreover, the localized nature of the disease in its early stages makes breast cancer an ideal model for the development of stathmin-based local therapy, which would help conserve the organ and avoid the morbidity and mortality associated with mastectomy and/or radiation therapy. In this study, we used an adenovirus-mediated gene therapy approach as a therapeutic strategy for targeting stathmin in vitro and in vivo models of human breast cancer. We had previously described the design and testing of several hammerhead ribozymes that selectively target stathmin messenger RNA (mRNA) for degradation in cancer cells. 20 We had also incorporated the genes that encode these ribozymes in adenoviral gene transfer vectors. 21 Here, we evaluated the therapeutic efficacy of the recombinant anti-stathmin adenovirus on the malignant phenotype of breast cancer cells as a single agent and in combination with chemotherapeutic agents in vitro and in vivo.
MATERIALS AND METHODS Reagents
Taxol (paclitaxel) and adriamycin were purchased from Sigma (St Louis, MO, USA). The drugs were dissolved in dimethyl sulfoxide as a 10 mM stock solution and stored at À 20 1C in aliquots.
Cell lines and cell culture conditions
The human breast cancer cell lines, T47D, SKBR-3 and MDA-MB-231 were purchased from the American Type Culture Collection. T47D and SKBR-3 cell lines were grown in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum, 100 units ml À 1 penicillin and 100 mg ml À 1 streptomycin. MDA-MB-231 cell line was grown in Dulbecco's modified Eagle medium-F12 medium supplemented with 10% fetal bovine serum, 100 units ml À 1 penicillin and 100 mg ml À 1 streptomycin. All cell lines were maintained at 37 1C in a humidified 5% CO 2 environment.
Recombinant adenoviral infections
We used a replication-deficient bicistronic adenovirus that co-express a green fluorescent protein (GFP) and an anti-stathmin ribozyme, Rz184, for targeting human stathmin mRNA. 20, 21 The control adenovirus contained the GFP reporter gene under the control of the CMV5 promotor without the anti-stathmin ribozyme sequences. For all adenoviral infections, cells were plated in 6-well culture plates 24 h before virus infection. After 24 h, cells were infected with the control adenovirus (adenovirus expressing GFP without ribozyme (Ad.GFP)) or anti-stathmin adenovirus (adenovirus expressing ribozyme and GFP (Ad.Rz.GFP)) at different multiplicities of infection (moi) ranging from 15 to 150 in a 2% reduced serum medium for 2-3 h. The virus was then removed and the cells were further incubated in complete growth medium. The efficiencies of the adenoviral infections were assessed by flow cytometry at 48 h after infection. The fraction of GFP-positive cells was determined using the WinList software (Verity Software House, Topsham, Maine, USA).
Western analysis
Uninfected cells and cells infected with either control Ad.GFP or Ad.Rz.GFP adenoviruses at moi of 100 were harvested 48 h after infection. The cell pellets were lysed for 30 min on ice in a buffer consisting of 50 mM Tris, pH 7.4, 150 mM NaCl and 1% Triton-X 100. The cell extracts were clarified by centrifugation and the protein concentrations were determined by using a Bio-Rad protein assay kit (Hercules, CA, USA). Twenty-five micrograms of each protein extract were electrophoresed in a 15% SDS-polyacrylamide gel, transferred to membrane and blocked in phosphate-buffered saline (PBS) containing 5% non-fat milk powder and 0.2% Tween 20 for 1 h at room temperature. The filter was incubated overnight at 4 1C with antistathmin antibody (BD Pharmingen, San Deigo, CA, USA) in PBS containing 0.1% Tween 20, followed by incubation with horseradish peroxidaseconjugated anti-mouse IgG (Sigma) for 2 h. The filter was then washed several times with PBS containing 0.2% Tween 20. As an internal control, the same filter was hybridized to anti-actin antibody (Oncogene Research Products, San Deigo, CA, USA), followed by incubation with horseradish peroxidase-conjugated anti-mouse IgM (Calbiochem, San Deigo, CA, USA) as above. The bands were visualized by chemiluminescence using an ECL kit (Amersham Biosciences, Piscataway, NJ, USA).
Cell proliferation assay
To assess the rate of proliferation, equal number of cells (2 Â 10 5 cells) were infected with either control Ad.GFP or Ad.Rz.GFP adenoviruses in triplicates at different mois. Cells were counted on a hemocytometer on alternate days, and growth curves were generated using the means of triplicate alternate-day cell counts. To assess the effects of anti-stathmin ribozyme on the proliferation of breast cancer cell lines in combination with chemotherapeutic agents, equal numbers of cells (2 Â 10 5 cells) were infected in triplicates with either control Ad.GFP or Ad.Rz.GFP anti-stathmin adenoviruses at a low moi of 25, as above. The infected cells were then cultured in the absence or presence of different concentrations of taxol or adriamycin, as indicated. Cells were counted on alternate days and the growth curves were generated as above.
Cell cycle distribution analysis
The distribution of cells in the different phases of the cell cycle was analyzed using the propidium iodide staining of fixed whole cells. Briefly, breast cancer cell lines were infected either with Ad.GFP or Ad.Rz.GFP adenoviruses at a moi of 100, as above. After 48 h, the cells were harvested, fixed in 70% ethanol, washed in PBS and resuspended for 30 min at 37 1C in 1 ml propidium iodide solution (PBS containing 0.05 mg ml À 1 propidium iodide, 0.1% sodium citrate and 1 mg ml À 1 RNase). DNA content was analyzed within 2 h in a Becton Dickinson (Bedford, MA, USA) FACStar Plus flow cytometer at 488 nm single laser excitation. The cell cycle distribution was analyzed using Win List software.
Anchorage-independent growth assay Anchorage-independent growth was assessed by colony formation in a methylcellulose semisolid medium. Briefly, equal numbers of cells were infected with either Ad.GFP or Ad.Rz.GFP in triplicates at different mois for 3 h. The cells were washed in PBS and resuspended in 5 ml methylcellulose-based semisolid medium (0.9% methylcellulose, 1% BSA and 0.1 mM b-mercaptoethanol prepared in Roswell Park Memorial Institute 1640 medium containing 30% fetal bovine serum, 100 units ml À 1 penicillin and 100 mg ml À 1 streptomycin). Cells (1 Â 10 4 ) were then plated in 6-well tissue culture plates in triplicates and incubated at 37 1C in 5% CO 2 atmosphere. The colonies that formed were counted after 2 weeks. For combination studies, the cells were infected with either Ad.GFP or Ad.Rz.GFP at a low moi of 25 and then incubated in the absence or presence of low concentrations of taxol (2 nM) or adriamycin (5 nM) for 3 days, and then resuspended in 5 ml methylcellulose-based semisolid medium and analyzed as above.
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Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay Cells were infected with either control Ad.GFP or Ad.Rz.GFP anti-stathmin adenoviruses, as above. Both floating and attached cells were harvested at 96 h after infection, and the effect of ribozyme-mediated stathmin inhibition on apoptosis was quantified using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay. DNA fragmentation was assessed by TUNEL assay using a cell death detection kit (Roche Applied Science, Indianapolis, IN, USA), according to the instructions of the manufacturer. Briefly, the cells were fixed, permeabilized and incubated with the TUNEL reaction mixture. The free 3 0 OH groups of fragmented DNA labeled with tetramethyl rhodaminelabeled nucleotides were quantified by flow cytometry. For combination studies, cells were infected with either Ad.GFP or Ad.Rz.GFP at a lower moi of 25, and then incubated in the absence or presence of low concentration of taxol (2 nM) or adriamycin (5 nM) for 96 h and analyzed by the TUNEL assay, as above.
In vivo xenograft studies
All the animal experiments were performed after obtaining approval from the Institutional Animal Care and Use Committee of Icahn School of Medicine at Mount Sinai, New York. All animals were housed in accordance with the institutional protocol for animal experiments.
Fifteen female nude mice were used to establish orthotopic breast cancer xenografts. MDA-MB-231 cells (5 Â 10 6 ) were injected into the left and right inguinal mammary gland (number 4) of each mice. Mice bearing established MDA-MB-231 xenografts were divided into three groups of five mice each. We initiated treatment by intratumoral injections after the mice developed tumors about 0.2-0.4 cm in size. Group 1 was injected with PBS, group II with the control Ad.GFP virus (10 10 viral particles (vp), once per week, for a total of three injections) and group III with the Ad.Rz.GFP adenovirus (10 10 vp, once per week, for a total of three injections). The animals were then closely monitored for the rate of tumor growth for 60 days. Tumor sizes were measured every 5 days, and relative tumor volumes were estimated by multiplying the longest diameter by the square of the shortest diameter and dividing by two. 22 The mean tumor volumes for each group were plotted against the number of days. To assess the efficiency of gene transfer, one animal was killed 1 week after the first intratumoral injection, with control Ad.GFP or Ad.Rz.GFP adenoviruses. The tumors were harvested immediately after killing and snap-frozen in liquid nitrogen for preparing tumor tissue sections for analysis of GFP expression. Images of tumor sections were captured on a Leica DM5500 microscope (Buffalo Grove, IL, USA), using the DFC-345 camera and the LAS-AF software (Buffalo Grove, IL, USA).
For in vivo combination studies, we used subtherapeutic doses of the recombinant adenovirus and chemotherapeutic agents. Thirty-five female nude mice were injected orthotopically in the mammary fat pad, as above. Treatment was initiated after the mice developed tumors of 0.2-0.4 cm in size. Mice bearing established MDA-MB-231 xenografts were divided into seven groups of five mice each. Group I was injected with PBS alone. Groups 2, 3 and 4 were injected with low dose of the control Ad.GFP (10 8 vp per injection). At the same time, low dose of adriamycin (5 mg kg À 1 per injection) and low dose of taxol (5 mg kg À 1 per injection) was coadministered in groups 3 and 4, respectively. Similarly, groups 5, 6 and 7 were injected with low dose of Ad.Rz.GFP (10 8 vp per injection) antistathmin adenovirus. Groups 6 and 7 were also treated with adriamycin and taxol, respectively, at the same doses. Tumor volumes were measured every 5 days and mean tumor volumes were plotted as above. All drugs were injected intraperitoneally and the adenoviruses were injected intratumorally once a week for a total of three injections.
Statistical analysis
The data are expressed as mean ± s.d. The data were analyzed for statistical significance using the two-tailed Student's t test. P valueso0.05 were considered statistically significant.
RESULTS
We used a replication-deficient bicistronic adenovirus that co-express GFP and an anti-stathmin ribozyme (Rz) for targeting human stathmin mRNA in breast cancer. 20, 21 The bicistronic nature of the recombinant adenovirus provides a unique advantage of tracking transfer of the therapeutic gene by GFP expression as a surrogate marker. We started our studies by testing the transduction efficiencies of our recombinant adenoviruses in different breast cancer cell lines (T47D, SKBR3 and MDA-MB-231). The efficiency of adenovirus infection was assessed by infecting different breast cell lines with anti-stathmin adenovirus at various mois ranging from 15 to 150. As controls, the cells were either mock infected or infected with the control Ad.GFP adenovirus at a similar moi to determine whether adenoviral infection results in cytotoxicity. We quantified the efficiency of gene transfer by assessing the fraction of cells that expressed GFP by flow cytometry. The optimal moi was determined to be in the range of 25-100. Infection of breast cancer cell lines with the recombinant adenoviruses resulted in an increase in the number of transduced cells with an increase in the moi. At a moi of 100, a vast majority of cells were transduced (480%) without significant cytotoxicity. Table 1 summarizes the transduction efficiencies of the recombinant adenoviruses at various mois in different breast cancer cell lines.
We then tested the effects of adenovirus-mediated gene transfer of anti-stathmin ribozyme on the level of stathmin expression in different breast cancer cell lines. (Figures 1a-c, lanes 1 and 2) . The same filter was hybridized to anti-actin antibody and the level of stathmin mRNA was normalized to actin to adjust for differences in RNA loading (Figure 1 ). These data demonstrates that adenovirus-mediated gene transfer of anti-stathmin ribozyme can efficiently downregulate stathmin expression in different breast cancer cell lines. Having confirmed the inhibition of stathmin, we next evaluated the effects of adenovirus-mediated gene transfer of anti-stathmin ribozyme as a single agent and in combination with chemotherapeutic agents on the malignant phenotype of breast cancer cells.
Effects of adenovirus-mediated gene transfer of anti-stathmin ribozyme as a single agent and in combination with chemotherapeutic agents on breast cancer cell proliferation In the first assay, we investigated the effects of anti-stathmin ribozyme on the rate of proliferation of different breast cancer cell lines. Figure 2 illustrates the rate of growth of different breast cancer To determine whether the growth inhibitory effects of stathmin inhibition on breast cancer cell proliferation can be further enhanced by chemotherapeutic agents, we used taxol and adriamycin, which are widely used in the treatment of breast cancer. For the combination studies, we used a lower moi of adenovirus and low doses of the drugs. The concentrations of the drugs that we used were all below half maximal inhibitory concentration and were determined in pilot experiments (data not shown). Figures 2c and d are representative growth curves, illustrating the effects of different concentrations of chemotherapeutic agents on the rate of proliferation of T47D cells in the presence and absence of stathmin inhibition. Exposure of T47D cells infected with the control Ad.GFP virus to taxol resulted in a modest dose-dependent decrease in the rate of proliferation (Figure 2c ). In contrast, exposure of T47D cells infected with Ad.Rz.GFP to the same concentrations of taxol resulted in a more profound decrease in proliferation, with a complete loss of proliferation at 4 nM of taxol (Figure 2c) . Thus, stathmin inhibition resulted in marked sensitization of T47D cells to the growth inhibitory effects of taxol. When T47D cells infected with Ad.Rz.GFP adenovirus were exposed to different concentrations of adriamycin, an increase in growth inhibitory effect was seen compared with cells infected with the control virus (Figure 2d) . However, the cells still continued to proliferate at a slower rate compared with control cells (Figure 2d ). This is not surprising as adriamycin does not exert its antitumor effects through the microtubules that make up the mitotic spindle. Similar findings were observed when Ad.Rz.GFP-infected MDA-MB-231 and SKBR3 cells were exposed to taxol or adriamycin (data not shown).
Effects of adenovirus-mediated gene transfer of anti-stathmin ribozyme as a single agent and in combination with chemotherapeutic agents on clonogenicity In a second assay, we examined the effects of the anti-stathmin adenovirus on the anchorage-independent growth potential of different breast cancer cell lines. The clonogenic anchorage-independent growth assay in semisolid medium is an in vitro assay of transformation, which has the best correlation with tumorigenicity in vivo.
23,24 Figure 3 illustrates the relative clonogenicity of different breast cancer cell lines either uninfected or infected with Ad.GFP or Ad.Rz.GFP at different mois. No significant differences were observed in the clonogenic potential of cells infected with the control Ad.GFP adenovirus compared with uninfected cells, as expected (Figure 3a) . In contrast, breast cancer cell lines infected with Ad.Rz.GFP adenovirus at different mois showed a dose-dependent inhibition of colony formation, with a near complete suppression of anchorage-independent growth in the different cell lines (Figure 3a) . At a moi of 100, the clonogenicity was reduced by 98%, 93% and 97% in Ad.Rz.GFPinfected T47D, SKBR3 and MDA-MB-231 breast cancer cell lines, respectively. These results demonstrate that adenovirus-mediated gene transfer of anti-stathmin ribozyme can inhibit tumorigenicity of different breast cancer cell lines in vitro.
We also examined the effects of adenovirus-mediated gene transfer of anti-stathmin ribozyme on the clonogenic potential of breast cancer cell lines in combination with chemotherapeutic agents like taxol and adriamycin. Figure 3b illustrates the clonogenicity of T47D cells, following exposure to low dose of anti-stathmin adenovirus and low dose of the drugs. Clonogenicity of cells infected with the control Ad.GFP virus was reduced by 23 and 20%, following exposure to taxol (Figure 3b (ii)) and adriamycin (Figure 3b (iii) ), respectively. The decrease in the clonogenic potential of Ad.GFP-infected cells upon exposure to the same drugs was nearly similar to that seen in uninfected cells (Figure 3b (ii) and (iii)). When cells were infected with Ad.Rz.GFP adenovirus, anti-stathmin ribozyme alone resulted in a 35% decrease in clonogenicity relative to control Ad.GFP-infected cells (Figure 3b (i) ). When Ad.Rz.GFP-infected cells were exposed to taxol, clonogenicity was significantly decreased by 97% (Figure 3b (ii) ). In comparison, clonogenicity of the same cells was only moderately reduced to 50% upon exposure to adriamycin (Figure 3b (iii) ). Thus, the observed decrease in clonogenicity following exposure to anti-stathmin adenovirus and taxol (Figure 3b (ii)) was much greater than the decrease in (Figure 3b (iii) ). The same combinations were tested in SKBR3 and MDA-MB-231 cells at different drug concentrations, and the observed anti-clonogenic effects in Ad.Rz.GFP-infected cells were always more potent in cells exposed to taxol than in cells exposed to adriamycin (data not shown).
Effects of adenovirus-mediated gene transfer of anti-stathmin ribozyme on apoptosis, as a single agent and in combination with chemotherapeutic agents In a third assay, we examined the effects of the anti-stathmin adenovirus on apoptosis in different breast cancer cell lines using a TUNEL assay (Figure 4 To investigate whether the chemotherapeutic agents could enhance the apoptotic effect mediated by anti-stathmin ribozyme, T47D cells were infected at a low moi of 25 and then exposed to low concentrations of either taxol or adriamycin. The cells infected with the control Ad.GFP virus showed a very small fraction of TUNEL-positive cells (1.1%), whereas infection with the Ad.Rz.GFP virus at a low moi resulted in slightly more TUNEL-positive cells (5.6%; Figure 4b ). When Ad.Rz.GFP-infected cells were exposed to taxol, the fraction of TUNEL-positive was increased to 35.4% (Figure 4b ). In contrast, when Ad.Rz.GFP-infected cells were exposed to adriamycin, the fraction of TUNEL-positive cells was increased to 12.6% (Figure 4b) . Thus, in this assay too, exposure to taxol resulted in a much greater increase in the fraction of TUNEL positivity in cells infected with Ad.Rz.GFP adenovirus compared with Ad.Rz.GFP-infected cells exposed to adriamycin. Thus, stathmin inhibition can greatly enhance the effects of taxol to result in greater inhibition of proliferation, clonogenicity and marked induction of apoptosis.
Efficacy of anti-stathmin therapy as a single agent and in combination with chemotherapeutic agents in vivo To investigate the efficacy of anti-stathmin therapy in vivo, we used an orthotopic model of breast cancer. In the orthotopic model, the breast cancer cells are injected directly into the mammary fat pad of the animal. 25 This places the tumor cells in a microenvironment that closely mimics the location in which the human disease develops. 25 Therefore, the orthotopic model is a more physiological model for the study of the effects of the therapeutic regimen in breast cancer. We used the MDA-MB-231 breast cancer cells for orthotopic implantation in athymic female nude mice. These cells are known to be tumorigenic when injected orthotopically in the mammary fat pad. 25, 26 Treatment was initiated by intratumoral injections after the mice developed tumors about 0.2-0.4 cm in size. One animal was killed 1 week after the first intratumoral injection with control Ad.GFP or Ad.Rz.GFP adenoviruses to assess the efficiency of gene transfer by GFP expression. GFP fluorescence was detected in a vast majority of cells in tumor derived from mice injected with control Ad.GFP or Ad.Rz.GFP adenoviruses (Figure 5a ). As each mouse had two tumors, one tumor from each mice was subjected to collagenase digestion to quantify the number of GFP-positive cells. By collagenase treatment also, a vast majority of the tumor cells were found to be GFP-positive (89%), confirming gene transfer of anti-stathmin ribozyme (data not shown). The remaining animals were then closely monitored for changes in the rate of tumor growth. Tumors injected with either PBS (Figure 5b) or the control Ad.GFP (Figure 5c ) continued to grow, whereas those injected with Ad.Rz.GFP anti-stathmin adenovirus showed a significant decrease in the rate of tumor growth (Figure 5d) . Histopathological evaluation of different organs did not show any signs of significant toxicity (data not shown).
To determine whether the therapeutic efficacy of stathmin inhibition could be further enhanced by combining it with standard chemotherapeutic agents in vivo, we examined the effects of low dose of anti-stathmin adenovirus in combination with low dose of chemotherapeutic drugs on tumor growth in nude mice ( Figure 6 ). The adenovirus and the drugs were administered at subtherapeutic doses, which were selected on the basis of dose response pilot experiments (data not shown). Tumors in animals injected with PBS or the control Ad.GFP continued to grow to larger sizes (Figures 6a and b, left panel) taxol, tumor regression (X40%) was observed in 60% of the tumors, and 40% of the tumors stopped growing completely (Figure 6c, right panel) . These findings demonstrate that the therapeutic efficacy of anti-stathmin therapy is markedly enhanced when combined with microtubule-interfering drugs like taxol than with adriamycin in vivo.
DISCUSSION
Breast cancer is one of the most frequently diagnosed malignancies and is the major leading cause of cancer-related deaths in women in the United States It is a very heterogeneous disease and the choice of treatment depends on the stage at disease presentation, hormone-receptor status and Her2/neu receptor status of the tumor. Although chemotherapy is widely used in the adjuvant, neoadjuvant and metastatic settings, such agents are generally active at the beginning of therapy in 90% of primary breast cancers and 50% of metastatic cases. However, after a considerable period, progression occurs because of drug resistance, which is a major obstacle to effective therapy. Furthermore, anti-estrogen hormonal therapy, which is generally used in the adjuvant setting, is associated with several undesirable side effects and an increase in the risk of endometrial cancers. Moreover, historically hormone therapy has never shown clinical benefit in ER-negative breast cancer and there is currently no treatment available for ER-negative breast cancer patients. Thus, there is clearly a pressing need for the development of new therapeutic strategies for this devastating malignancy.
In this study, we investigated whether stathmin can serve as a viable molecular target in breast cancer using a gene therapy approach. We used different cell culture models that represent a spectrum of ER-positive and ER-negative breast cancer cell lines with different levels of stathmin expression. 12 High levels of stathmin expression have been shown to correlate with the loss of ER in breast cancer samples. 12, 16 Consistent with these findings in patient specimens, the ER-negative cell lines have been previously shown to express higher levels of stathmin than ER-positive cell lines. 12 Our studies demonstrate that adenovirus-mediated gene transfer of anti-stathmin ribozyme can effectively suppress the proliferation and anchorage-independent growth by inducing G2/M arrest and apoptosis in both, ER-positive (T47D) and ERnegative (SKBR3, MDA-MB-231) breast cancer cell lines. This suggests that the therapeutic effects of anti-stathmin adenovirus can be generalized to both ER-positive and ER-negative breast cancer cell lines. Previous studies showed that stathmin is negatively regulated by p53 and is transcriptionally repressed by functional p53 and derepressed in the presence of mutant p53. 27, 28 The observed antiproliferative effects in breast cancer cells as a result of adenovirus-mediated gene transfer of antistathmin ribozyme are consistent with the studies of Alli et al. 29 who demonstrated that silencing of stathmin induces tumor suppressor function in breast cancer cell lines harboring mutant p53. Furthermore, our studies also demonstrated significant inhibition of the growth of mammary tumors in nude mice, following adenovirus-mediated anti-stathmin therapy (Figure 5b ). The inhibition of tumor growth correlated with a vast majority of tumor cells infected with the recombinant adenovirus (Figure 5a ). In contrast, mammary tumors treated with a lower dose of antistathmin therapy showed a modest decrease in the growth of tumors (Figure 6c ), which corresponded with o50% GFP-positive cells in tumors treated with the recombinant adenovirus (data not shown). As there was a dose-dependent inhibition of tumor growth, it is unlikely that the observed anti-tumorigenic effects in vivo is a result of potential by standard effects.
Conventional chemotherapy in advanced breast cancer is largely ineffective because of the inherent chemoresistance. Taxol is an effective chemotherapeutic agent against breast cancer.
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The taxanes are a family of mitotic inhibitors that exert their antitumor effects by stabilizing the microtubules that make up the mitotic spindle. Although taxol has marked cytotoxic activity against breast cancer cells in vitro, the results of clinical studies in which taxol was used as a single agent in the treatment of this neoplasm have been disappointing. 31 ,32 Thus, we tested whether combination of two interventions, which interfere with normal cell cycle progression through its effects on microtubules (that is, taxol exposure and anti-stathmin therapy), will have more potent antitumor activity than either treatment alone. Our studies of the effects of the anti-stathmin therapy in combination with taxol demonstrated significantly greater inhibition of growth in different breast cancer cell lines in vitro as well as in vivo compared with either agent alone. Previous studies have shown that stathmin deficiency decreases the rate of catastrophes and sequestration of tubulin molecules, thereby shifting the equilibrium between the polymerized and unpolymerized tubulin in favor of the polymerized tubulin. 8, 11, 33, 34 Taxol, on the other hand, stabilizes microtubules by binding to polymerized tubulin. 35 Thus, it is not surprising that ribozyme-mediated stathmin-inhibited cells, when exposed to taxol will have difficulty depolymerizing the microtubules because of stathmin deficiency, and the polymerized microtubules will be further stabilized by taxol binding, leading to more profound inhibition of growth. In contrast, the intercalating agent adriamycin failed to mediate significant growth inhibition in vitro and in vivo, compared with taxol. This may be because the activity of adriamycin does not result from direct interactions with microtubules and the mitotic spindle. Although inhibition of tumor growth was observed in both the combination treatment groups compared with groups treated with single agent alone, combination of anti-stathmin therapy and taxol had a more profound inhibition of tumorigenicity. The combination of taxol with gene therapy directed against stathmin is attractive as both interventions target the same mitotic pathway. Such moleculartargeted therapies may be designed in combination with taxanes at much lower doses than at their maximum tolerated doses. This would avoid toxicities associated with the use of multiple chemotherapeutic agents at full therapeutic doses. Clinically, these findings are highly relevant because taxol is one of the most active chemotherapeutic agents used in the treatment of breast cancer. The findings of our study are consistent with a recent retrospective study, which demonstrated that low expression of stathmin in tumors predict high response to neoadjuvant chemotherapy, with docetaxel containing regimens in locally advanced breast cancer. 36 Furthermore, low stathmin was associated with better prognosis in breast cancer cohorts. 36, 37 Overexpression of stathmin in breast cancer cell lines, on the other hand, was shown to be associated with reduced taxane sensitivity and increased resistance to taxane-based therapy owing to decreased binding of taxol to microtubules and delayed entry into mitosis. 38 This suggests that the level of stathmin can strongly influence the activity of taxanes in breast cancer.
Overall, our studies provide the proof-of-principle that stathmin is an excellent target for breast cancer therapy and could serve as the primary focus of novel approaches to the treatment of breast cancer. Although the gene therapy approach described in this study may be applicable to only a small fraction of breast cancer patients with mainly local/regional disease, in order to make a significant impact on the way breast cancer is treated at a global level, identification of small molecule inhibitors of stathmin function might be critically important for the development of novel therapeutics for breast cancer. The development of such small molecules into effective drugs, which could be administered in combination with taxol and/or other chemotherapeutic agents, may lead to highly effective therapeutic strategies for localized and advanced breast cancer.
